{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:58:48Z","timestamp":1792511928012,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"28","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011841","name":"Xinxiang Medical University","doi-asserted-by":"publisher","award":["XYBSKYZZ201609"],"award-info":[{"award-number":["XYBSKYZZ201609"]}],"id":[{"id":"10.13039\/501100011841","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.vaccine.2023.05.049","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T07:05:13Z","timestamp":1684739113000},"page":"4067-4080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Incidence of myopericarditis after mRNA COVID-19 vaccination: A meta-analysis with focus on adolescents aged 12\u201317\u00a0years"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7321-809X","authenticated-orcid":false,"given":"Bao-Qiang","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Qiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.vaccine.2023.05.049_b0005","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2107456","article-title":"Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents","volume":"385","author":"Frenck","year":"2021","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.vaccine.2023.05.049_b0010","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.vaccine.2023.05.049_b0015","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1056\/NEJMoa2109522","article-title":"Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents","volume":"385","author":"Ali","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2023.05.049_b0020","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1177\/01410768211052589","article-title":"Vaccinating adolescents against SARS-CoV-2 in England: a risk-benefit analysis","volume":"114","author":"Gurdasani","year":"2021","journal-title":"J R Soc Med"},{"issue":"7","key":"10.1016\/j.vaccine.2023.05.049_b0025","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S2213-2600(22)00059-5","article-title":"Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis","volume":"10","author":"Ling","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.vaccine.2023.05.049_b0030","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1001\/jamapediatrics.2022.0101","article-title":"Myocarditis following COVID-19 BNT162b2 vaccination among adolescents in Hong Kong","volume":"176","author":"Li","year":"2022","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.vaccine.2023.05.049_b0035","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372:n71","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.vaccine.2023.05.049_b0040","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S2215-0366(15)00376-4","article-title":"Prevalence of autism spectrum disorder phenomenology in genetic disorders: a systematic review and meta-analysis","volume":"2","author":"Richards","year":"2015","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"10.1016\/j.vaccine.2023.05.049_b0045","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/acps.13170","article-title":"Blood biomarker levels of methylation capacity in autism spectrum disorder: a systematic review and meta-analysis","volume":"141","author":"Guo","year":"2020","journal-title":"Acta Psychiatr Scand"},{"issue":"14","key":"10.1016\/j.vaccine.2023.05.049_b0050","doi-asserted-by":"crossref","first-page":"517","DOI":"10.15585\/mmwr.mm7114e1","article-title":"Cardiac complications after SARS-CoV-2 Infection and mRNA COVID-19 vaccination - PCORnet, United States, January 2021-January 2022","volume":"71","author":"Block","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"10.1016\/j.vaccine.2023.05.049_b0055","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2022-057508","article-title":"Risk of myopericarditis after COVID-19 vaccination in Danish children aged 5 to 11 years","volume":"150","author":"Nygaard","year":"2022","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.vaccine.2023.05.049_b0060","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.18505","article-title":"Epidemiology of myocarditis and pericarditis following mRNA vaccination by vaccine product, schedule, and interdose interval among adolescents and adults in Ontario, Canada","volume":"5","author":"Buchan","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.vaccine.2023.05.049_b0065","doi-asserted-by":"crossref","DOI":"10.1136\/bmjpo-2022-001472","article-title":"Myocarditis and myopericarditis cases following COVID-19 mRNA vaccines administered to 12\u201317-year olds in Victoria, Australia","volume":"6","author":"Cheng","year":"2022","journal-title":"BMJ Paediatr Open"},{"issue":"4","key":"10.1016\/j.vaccine.2023.05.049_b0070","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/cid\/ciab989","article-title":"Epidemiology of acute myocarditis\/pericarditis in Hong Kong adolescents following comirnaty vaccination","volume":"75","author":"Chua","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2023.05.049_b0075","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.7326\/M22-2274","article-title":"Incidence of myocarditis\/pericarditis following mRNA COVID-19 vaccination among children and younger adults in the United States","volume":"175","author":"Goddard","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2023.05.049_b0080","doi-asserted-by":"crossref","unstructured":"Hu M, Wong HL, Feng Y, et al. Results of safety monitoring of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine in U.S. children aged 5-17 years. medRxiv 2022; published online October 30. https:\/\/doi.org\/10.1101\/2022.10.28.22281532 (preprint).","DOI":"10.1101\/2022.10.28.22281532"},{"issue":"3","key":"10.1016\/j.vaccine.2023.05.049_b0085","doi-asserted-by":"crossref","first-page":"230","DOI":"10.24171\/j.phrp.2022.0122","article-title":"Safety monitoring of COVID-19 vaccination among adolescents aged 12 to 17 years old in the Republic of Korea","volume":"13","author":"Kim","year":"2022","journal-title":"Osong Public Health Res Perspect"},{"issue":"5","key":"10.1016\/j.vaccine.2023.05.049_b0090","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13759","article-title":"BNT162b2 Vaccine-Associated Myo\/Pericarditis in Adolescents: A Stratified Risk-Benefit Analysis","volume":"52","author":"Krug","year":"2022","journal-title":"Eur J Clin Invest"},{"issue":"10","key":"10.1016\/j.vaccine.2023.05.049_b0095","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMc2116999","article-title":"Myocarditis after BNT162b2 Vaccination in Israeli Adolescents","volume":"386","author":"Mevorach","year":"2022","journal-title":"N Engl J Med"},{"issue":"45","key":"10.1016\/j.vaccine.2023.05.049_b0100","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.220676","article-title":"Observed versus expected rates of myocarditis after SARS-CoV-2 vaccination: a population-based cohort study","volume":"194","author":"Naveed","year":"2022","journal-title":"CMAJ"},{"issue":"1","key":"10.1016\/j.vaccine.2023.05.049_b0105","doi-asserted-by":"crossref","DOI":"10.1097\/INF.0000000000003389","article-title":"Population-based incidence of myopericarditis after COVID-19 vaccination in Danish adolescents","volume":"41","author":"Nygaard","year":"2022","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2023.05.049_b0110","unstructured":"Shimabukuro T. Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP). Update on COVID-19 vaccine safety, including myocarditis after mRNA vaccines. June 23, 2021. https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-06\/03-COVID-Shimabukuro-508.pdf."},{"key":"10.1016\/j.vaccine.2023.05.049_b0115","unstructured":"Su JR. Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP). COVID-19 vaccine safety updates: Primary series in children and adolescents ages 5\u201311 and 12\u201315 years, and booster doses in adolescents ages 16\u201324 years. January 5, 2022. https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2022-01-05\/02-covid-su-508.pdf."},{"key":"10.1016\/j.vaccine.2023.05.049_b0120","doi-asserted-by":"crossref","unstructured":"Su WJ, Liu YL, Chang CH, et al. Risk of Myocarditis and Pericarditis Following Coronavirus Disease 2019 Messenger RNA Vaccination\u2014A Nationwide Study. medRxiv 2022; published online October 13. https:\/\/doi.org\/10.1101\/2022.10.11.22280860 (preprint).","DOI":"10.1101\/2022.10.11.22280860"},{"issue":"19","key":"10.1016\/j.vaccine.2023.05.049_b0125","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1056\/NEJMc2207270","article-title":"Myocarditis after BNT162b2 Vaccination in Israeli Adolescents","volume":"387","author":"Witberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.05.049_b0130","article-title":"Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study","volume":"373","author":"Li","year":"2021","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.vaccine.2023.05.049_b0135","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41569-021-00662-w","article-title":"Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms","volume":"19","author":"Heymans","year":"2022","journal-title":"Nat Rev Cardiol"},{"issue":"11","key":"10.1016\/j.vaccine.2023.05.049_b0140","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S2352-4642(22)00244-9","article-title":"Outcomes at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults in the USA: a follow-up surveillance study","volume":"6","author":"Kracalik","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"issue":"1","key":"10.1016\/j.vaccine.2023.05.049_b0145","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamapediatrics.2022.4768","article-title":"Myopericarditis after COVID-19 mRNA vaccination among adolescents and young adults: A systematic review and meta-analysis","volume":"177","author":"Yasuhara","year":"2023","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.vaccine.2023.05.049_b0150","article-title":"Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review","volume":"378","author":"Pillay","year":"2022","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.vaccine.2023.05.049_b0155","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/j.vaccine.2022.02.017","article-title":"Myocarditis following mRNA Covid-19 vaccination: A pooled analysis","volume":"40","author":"Bellos","year":"2022","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2023.05.049_b0160","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/bcp.15625","article-title":"A narrative review of vaccine pharmacovigilance during mass vaccination campaigns: Focus on myocarditis and pericarditis after COVID-19 mRNA vaccination","volume":"89","author":"Pich\u00e9-Renaud","year":"2023","journal-title":"Br J Clin Pharmacol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23006102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23006102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:26:56Z","timestamp":1759404416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23006102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":32,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0264410X23006102"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.05.049","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of myopericarditis after mRNA COVID-19 vaccination: A meta-analysis with focus on adolescents aged 12\u201317\u00a0years","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.05.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}